Omeros Corporation
Clinical trials sponsored by Omeros Corporation, explained in plain language.
-
New drug shows promise in early trial for rare blood disorder
Disease control CompletedThis early study tested an experimental drug called OMS906 (zaltenibart) in 15 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where red blood cells break apart. The main goal was to check safety and how the body handles the drug. Researchers also look…
Phase: PHASE1 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for PNH patients: experimental drug OMS906 shows promise in early trial
Disease control CompletedThis study tested a new drug called OMS906 in 12 adults with paroxysmal nocturnal hemoglobinuria (PNH) who were not getting enough benefit from the standard treatment ravulizumab. The goal was to see if OMS906 is safe and can improve hemoglobin levels. Participants received OMS90…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC